Determinants of Infection Outcome in HCV-Genotype 4

Viral Immunol. 2017 Oct;30(8):560-567. doi: 10.1089/vim.2017.0071. Epub 2017 Jul 21.

Abstract

Hepatitis C virus (HCV) infection represents a worldwide health problem and has been for long an attractive point of research due to diversity among different genotypes regarding unique geographical distribution and diverse treatment outcome. HCV is considered a major cause of chronic liver disease and cirrhosis, which leads to liver failure and hepatocellular carcinoma requiring liver transplantation. Of the HCV genotypes identified, HCV genotype 4 (HCV-4) is the least studied. HCV-4 is responsible for ∼10% of HCV infections and is common in the Middle East and Africa; recently it is increasingly prevalent in European Countries. HCV-4 is a continuing epidemic in Egypt, having the highest prevalence of HCV worldwide. "Know your epidemic, know your response" concept necessitates better understanding of HCV-4 characteristics to control disease dissemination and progression, which compromises the life quality of chronic HCV-infected patients. In this review, we discuss the epidemiology, natural history, and treatment options for patients with HCV-4 infection.

Keywords: HCV-4; epidemiology; natural history; treatment.

Publication types

  • Review

MeSH terms

  • Africa / epidemiology
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Clinical Trials as Topic
  • Disease Progression
  • Europe / epidemiology
  • Female
  • Genotype
  • Hepacivirus* / genetics
  • Hepatitis C, Chronic* / epidemiology
  • Hepatitis C, Chronic* / prevention & control
  • Hepatitis C, Chronic* / therapy
  • Hepatitis C, Chronic* / transmission
  • Humans
  • Male
  • Middle East / epidemiology
  • Prevalence
  • RNA, Viral / genetics
  • Risk Factors
  • Treatment Outcome

Substances

  • Antiviral Agents
  • RNA, Viral